长春高新(000661) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 2.78 billion, a decrease of 6.63% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 856.99 million, down 24.71% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 854.01 million, a decline of 23.93% compared to the previous year[5]. - Basic earnings per share decreased to CNY 2.13, down 24.73% from CNY 2.83 in the same period last year[5]. - Net profit for the period was CNY 1,047,130,861.22, down 23.7% from CNY 1,372,310,481.87 in the same quarter last year[21]. - The net profit for Q1 2023 was ¥859,198,906.19, a decrease of 25% compared to ¥1,145,274,026.14 in Q1 2022[22]. - The total comprehensive income for Q1 2023 was ¥852,300,642.03, down from ¥1,133,849,287.35 in the same period last year[22]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 55.21% to CNY 936.67 million[5]. - Cash and cash equivalents at the end of Q1 2023 were CNY 6,001,830,360.88, up 7.6% from CNY 5,578,512,789.74 at the beginning of the year[15]. - Operating cash flow for Q1 2023 was ¥936,665,805.67, an increase of 55% compared to ¥603,486,976.75 in Q1 2022[24]. - The company reported a net cash increase of ¥360,421,074.68 for the quarter, contrasting with a decrease of ¥284,724,036.90 in Q1 2022[25]. - The cash flow from financing activities showed a net outflow of -¥83,894,379.73, improving from -¥496,264,533.70 in the same quarter last year[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 26.77 billion, an increase of 2.87% from the end of the previous year[5]. - Total assets increased to CNY 26,774,571,937.99, compared to CNY 26,027,362,994.80 at the start of the year, reflecting a growth of 2.9%[18]. - Total liabilities decreased to CNY 5,080,624,430.21 from CNY 5,220,865,791.33, a reduction of 2.7%[18]. - The company’s total equity rose to CNY 21,693,947,507.78, an increase of 4.3% from CNY 20,806,497,203.47 at the beginning of the year[18]. Research and Development - R&D expenses increased by 42.81% year-on-year, amounting to CNY 3.34 billion, primarily due to increased investment in the pharmaceutical subsidiary[9]. - R&D expenses rose significantly to CNY 334,939,252.04, an increase of 42.7% compared to CNY 234,535,809.05 in the previous year[21]. Subsidiary Performance - The subsidiary Jinsai Pharmaceutical achieved revenue of CNY 2.35 billion and a net profit of CNY 895 million[9]. - The company reported a 36.38% decrease in accounts receivable notes, totaling CNY 0.88 billion, mainly due to increased payments from the pharmaceutical subsidiary[9].